Brief: Intercept Expects To Complete Planned Interim Analyses From 2 Ongoing Phase 2 Studies Of OCA-bezafibrate In 2023
27/04/2023 12:18
April 27 (Reuters) - Intercept Pharmaceuticals Inc
ICPT.O :
* INTERCEPT ANNOUNCES NEW DATA TO BE PRESENTED AT THE
EUROPEAN
ASSOCIATION FOR THE STUDY OF THE LIVER (EASL) CONGRESS 2023 AND
PROVIDES UPDATE ON OCA-BEZAFIBRATE FIXED-DOSE COMBINATION (FDC)
DEVELOPMENT PROGRAM
* INTERCEPT PHARMACEUTICALS - EXPECTS TO COMPLETE PLANNED
INTERIM
ANALYSES FROM 2 ONGOING PHASE 2 STUDIES OF OCA-BEZAFIBRATE IN
2023
Source text for Eikon: ID:nGNX6qGmd0
Further company coverage: ICPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intercept Pharmaceuticals
See all newsIntercept Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Digitalbridge Group, Huntington Ingalls Industries, Workday
U.S. RESEARCH ROUNDUP-Docusign, Immunovant, Liberty Energy
U.S. STOCKS ON THE MOVE-Amazon, United Parcel Service, Nike
U.S. STOCKS ON THE MOVE-BullFrog AI, Soleno,